As the coronavirus vaccine rollout is rapidly underway, many questions still remain regarding who should first receive it, its efficacy against new strains of the virus, and domestic and global cooperation in its creation and distribution. Dr. Peggy Hamburg, an internationally recognized leader in public health and medicine, touched on her experience with the U.S. Food and Drug Administration to explore these concerns regarding the vaccine and its future. She also considered the lessons of COVID-19 in the context of broader biosecurity threats.
This event was hosted through Georgetown University’s Conversations in Global Health class, which invites global health professionals to Georgetown’s campus to engage in discussions regarding their career paths and expertise. John Monahan guides the structured conversation, and the discussion is open to all Georgetown University faculty, students, and staff.
Featured
Dr. Margaret “Peggy” Hamburg is the interim vice president of global biological policy and program at the Nuclear Threat Initiative. She recently stepped down as foreign secretary of the National Academy of Medicine, and previously she was president of the American Association for the Advancement of Science, commissioner of the U.S. Food and Drug Administration, and health commissioner of New York City.
John Monahan is the senior advisor for global health to President John J. DeGioia; senior fellow, McCourt School of Public Policy; and senior scholar, O'Neill Institute for National and Global Health Law.
